Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 474

1.

Ex vivo culture of mouse skin activates an interleukin 1 alpha-dependent inflammatory response.

Zhou HM, Slominski RM, Seymour LJ, Bell MC, Dave P, Atumonye J, Wright W 3rd, Dawes A, Griesenauer B, Paczesny S, Kaplan MH, Spandau DF, Turner MJ.

Exp Dermatol. 2019 Sep 30. doi: 10.1111/exd.14044. [Epub ahead of print]

PMID:
31566815
2.

A phase Ib study of a PI3Kinase inhibitor BKM120 in combination with panitumumab in patients with KRAS wild-type advanced colorectal cancer.

Goodwin R, Jonker D, Chen E, Kennecke H, Cabanero M, Tsao MS, Vickers M, Bohemier C, Lim H, Ritter H, Tu D, Seymour L.

Invest New Drugs. 2019 Sep 10. doi: 10.1007/s10637-019-00814-3. [Epub ahead of print]

PMID:
31506897
3.

Use of Liquid Patient Ascites Fluids as a Preclinical Model for Oncolytic Virus Activity.

Scott EM, Frost S, Khalique H, Freedman JD, Seymour LW, Lei-Rossmann J.

Methods Mol Biol. 2020;2058:261-270. doi: 10.1007/978-1-4939-9794-7_17.

PMID:
31486044
4.

A Phase Ib Trial of Durvalumab in Combination with Trastuzumab in HER2-Positive Metastatic Breast Cancer (CCTG IND.229).

Chia S, Bedard PL, Hilton J, Amir E, Gelmon K, Goodwin R, Villa D, Cabanero M, Tu D, Tsao M, Seymour L.

Oncologist. 2019 Aug 16. pii: theoncologist.2019-0321. doi: 10.1634/theoncologist.2019-0321. [Epub ahead of print]

PMID:
31420468
5.

Dose-Ranging and Cohort-Expansion Study of Monalizumab (IPH2201) in Patients with Advanced Gynecologic Malignancies: A Trial of the Canadian Cancer Trials Group (CCTG): IND221.

Tinker AV, Hirte HW, Provencher D, Butler M, Ritter H, Tu D, Azim HA Jr, Paralejas P, Grenier N, Hahn SA, Ramsahai J, Seymour L.

Clin Cancer Res. 2019 Oct 15;25(20):6052-6060. doi: 10.1158/1078-0432.CCR-19-0298. Epub 2019 Jul 15.

PMID:
31308062
6.

Selumetinib in patients receiving standard pemetrexed and platinum-based chemotherapy for advanced or metastatic KRAS wildtype or unknown non-squamous non-small cell lung cancer: A randomized, multicenter, phase II study. Canadian Cancer Trials Group (CCTG) IND.219.

Melosky B, Bradbury P, Tu D, Florescu M, Reiman A, Nicholas G, Basappa N, Rothenstein J, Goffin JR, Laurie SA, Wheatley-Price P, Leighl N, Goss G, Reaume MN, Butts C, Murray N, Card C, Ko J, Blais N, Gray S, Lui H, Brown-Walker P, Kaurah P, Prentice LM, Seymour L.

Lung Cancer. 2019 Jul;133:48-55. doi: 10.1016/j.lungcan.2019.04.027. Epub 2019 May 1.

PMID:
31200828
7.

Anti-PD-1 Immunotherapy-Induced Flare of a Known Underlying Relapsing Vasculitis Mimicking Recurrent Cancer.

Nabel CS, Severgnini M, Hung YP, Cunningham-Bussel A, Gjini E, Kleinsteuber K, Seymour LJ, Holland MK, Cunningham R, Felt KD, Vivero M, Rodig SJ, Massarotti EM, Rahma OE, Harshman LC.

Oncologist. 2019 Aug;24(8):1013-1021. doi: 10.1634/theoncologist.2018-0633. Epub 2019 May 14.

PMID:
31088979
8.

Nanomedicines for the Delivery of Biologics.

Wahlich J, Desai A, Greco F, Hill K, Jones AT, Mrsny RJ, Pasut G, Perrie Y, Seib FP, Seymour LW, Uchegbu IF.

Pharmaceutics. 2019 May 3;11(5). pii: E210. doi: 10.3390/pharmaceutics11050210.

9.

A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration-resistant Prostate Cancer: Canadian Cancer Trials Group Study IND205.

Hotte SJ, Chi KN, Joshua AM, Tu D, Macfarlane RJ, Gregg RW, Ruether JD, Basappa NS, Finch D, Salim M, Winquist EW, Torri V, North S, Kollmannsberger C, Ellard SL, Eigl BJ, Tinker A, Allan AL, Beja K, Annala M, Powers J, Wyatt AW, Seymour L; Canadian Cancer Trials Group (formerly NCIC Clinical Trials Group).

Clin Genitourin Cancer. 2019 Jun;17(3):201-208.e1. doi: 10.1016/j.clgc.2019.03.005. Epub 2019 Mar 15.

PMID:
31056399
10.

Polyvalent Diazonium Polymers Provide Efficient Protection of Oncolytic Adenovirus Enadenotucirev from Neutralizing Antibodies while Maintaining Biological Activity In Vitro and In Vivo.

Francini N, Cochrane D, Illingworth S, Purdie L, Mantovani G, Fisher K, Seymour LW, Spain SG, Alexander C.

Bioconjug Chem. 2019 Apr 17;30(4):1244-1257. doi: 10.1021/acs.bioconjchem.9b00189. Epub 2019 Mar 27.

PMID:
30874432
11.

RECIST 1.1 for Response Evaluation Apply Not Only to Chemotherapy-Treated Patients But Also to Targeted Cancer Agents: A Pooled Database Analysis.

Litière S, Isaac G, De Vries EGE, Bogaerts J, Chen A, Dancey J, Ford R, Gwyther S, Hoekstra O, Huang E, Lin N, Liu Y, Mandrekar S, Schwartz LH, Shankar L, Therasse P, Seymour L; RECIST Working Group.

J Clin Oncol. 2019 May 1;37(13):1102-1110. doi: 10.1200/JCO.18.01100. Epub 2019 Mar 12.

PMID:
30860949
12.

Impact of Polymer-TLR-7/8 Agonist (Adjuvant) Morphology on the Potency and Mechanism of CD8 T Cell Induction.

Lynn GM, Chytil P, Francica JR, Lagová A, Kueberuwa G, Ishizuka AS, Zaidi N, Ramirez-Valdez RA, Blobel NJ, Baharom F, Leal J, Wang AQ, Gerner MY, Etrych T, Ulbrich K, Seymour LW, Seder RA, Laga R.

Biomacromolecules. 2019 Feb 11;20(2):854-870. doi: 10.1021/acs.biomac.8b01473. Epub 2019 Jan 22.

PMID:
30608149
13.

Seamless Designs: Current Practice and Considerations for Early-Phase Drug Development in Oncology.

Hobbs BP, Barata PC, Kanjanapan Y, Paller CJ, Perlmutter J, Pond GR, Prowell TM, Rubin EH, Seymour LK, Wages NA, Yap TA, Feltquate D, Garrett-Mayer E, Grossman W, Hong DS, Ivy SP, Siu LL, Reeves SA, Rosner GL.

J Natl Cancer Inst. 2019 Feb 1;111(2):118-128. doi: 10.1093/jnci/djy196.

14.

Optogenetic control of iPS cell-derived neurons in 2D and 3D culture systems using channelrhodopsin-2 expression driven by the synapsin-1 and calcium-calmodulin kinase II promoters.

Lee SY, George JH, Nagel DA, Ye H, Kueberuwa G, Seymour LW.

J Tissue Eng Regen Med. 2019 Mar;13(3):369-384. doi: 10.1002/term.2786. Epub 2019 Jan 30.

15.

Antagonism of Glycolysis and Reductive Carboxylation of Glutamine Potentiates Activity of Oncolytic Adenoviruses in Cancer Cells.

Dyer A, Schoeps B, Frost S, Jakeman P, Scott EM, Freedman J, Jacobus EJ, Seymour LW.

Cancer Res. 2019 Jan 15;79(2):331-345. doi: 10.1158/0008-5472.CAN-18-1326. Epub 2018 Nov 28.

PMID:
30487139
16.

An Oncolytic Virus Expressing a T-cell Engager Simultaneously Targets Cancer and Immunosuppressive Stromal Cells.

Freedman JD, Duffy MR, Lei-Rossmann J, Muntzer A, Scott EM, Hagel J, Campo L, Bryant RJ, Verrill C, Lambert A, Miller P, Champion BR, Seymour LW, Fisher KD.

Cancer Res. 2018 Dec 15;78(24):6852-6865. doi: 10.1158/0008-5472.CAN-18-1750. Epub 2018 Nov 18.

PMID:
30449733
17.

LACE-Bio: Validation of Predictive and/or Prognostic Immunohistochemistry/Histochemistry-based Biomarkers in Resected Non-small-cell Lung Cancer.

Seymour L, Le Teuff G, Brambilla E, Shepherd FA, Soria JC, Kratzke R, Graziano S, Douillard JY, Rosell R, Reiman A, Lacas B, Lueza B, Aviel-Ronen S, McLeer A, Le Chevalier T, Pirker R, Filipits M, Dunant A, Pignon JP, Tsao MS; LACE-Bio Steering Committee.

Clin Lung Cancer. 2019 Mar;20(2):66-73.e6. doi: 10.1016/j.cllc.2018.10.001. Epub 2018 Oct 11.

PMID:
30414783
18.

Phase I study of vinblastine and temsirolimus in pediatric patients with recurrent or refractory solid tumors: Canadian Cancer Trials Group Study IND.218.

Deyell RJ, Wu B, Rassekh SR, Tu D, Samson Y, Fleming A, Bouffet E, Sun X, Powers J, Seymour L, Baruchel S, Morgenstern DA.

Pediatr Blood Cancer. 2019 Mar;66(3):e27540. doi: 10.1002/pbc.27540. Epub 2018 Nov 4.

PMID:
30393943
19.

Separation, banking, and quality control of peripheral blood mononuclear cells from whole blood of melanoma patients.

Holland M, Cunningham R, Seymour L, Kleinsteuber K, Cunningham A, Patel T, Manos M, Brennick R, Zhou J, Hodi FS, Severgnini M.

Cell Tissue Bank. 2018 Dec;19(4):783-790. doi: 10.1007/s10561-018-9734-x. Epub 2018 Oct 30.

PMID:
30377864
20.

Canadian Cancer Trials Group (CCTG) IND215: A phase Ib study of Selumetinib in patients with untreated advanced or metastatic NSCLC who are receiving standard chemotherapy regimens.

Goffin JR, Nicholas G, Mates M, Tu D, Chen E, Laurie SA, Juergens R, Robinson A, Goss G, Reaume M, Sun S, Christink K, Maize C, MacFarlan S, Sun X, Ritter H, Seymour L, Bradbury PA.

Invest New Drugs. 2019 Jun;37(3):498-506. doi: 10.1007/s10637-018-0680-z. Epub 2018 Oct 13.

PMID:
30317534
21.

Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies.

Smoragiewicz M, Bogaerts J, Calvo E, Marabelle A, Perrone A, Seymour L, Shalabi A, Siu LL, Tabernero J, Giaccone G; task force on Methodology for the Development of Innovative Cancer Therapies.

Ann Oncol. 2018 Nov 1;29(11):2175-2182. doi: 10.1093/annonc/mdy398.

PMID:
30202892
22.

Turning cold tumours hot: oncolytic virotherapy gets up close and personal with other therapeutics at the 11th Oncolytic Virus Conference.

Dyer A, Baugh R, Chia SL, Frost S, Iris, Jacobus EJ, Khalique H, Pokrovska TD, Scott EM, Taverner WK, Seymour LW, Lei J.

Cancer Gene Ther. 2019 Mar;26(3-4):59-73. doi: 10.1038/s41417-018-0042-1. Epub 2018 Sep 4.

PMID:
30177818
23.

Tumor Mutation Burden as a Biomarker in Resected Non-Small-Cell Lung Cancer.

Devarakonda S, Rotolo F, Tsao MS, Lanc I, Brambilla E, Masood A, Olaussen KA, Fulton R, Sakashita S, McLeer-Florin A, Ding K, Le Teuff G, Shepherd FA, Pignon JP, Graziano SL, Kratzke R, Soria JC, Seymour L, Govindan R, Michiels S.

J Clin Oncol. 2018 Oct 20;36(30):2995-3006. doi: 10.1200/JCO.2018.78.1963. Epub 2018 Aug 14.

PMID:
30106638
24.

Genome-wide copy number analyses of samples from LACE-Bio project identify novel prognostic and predictive markers in early stage non-small cell lung cancer.

Rotolo F, Zhu CQ, Brambilla E, Graziano SL, Olaussen K, Le-Chevalier T, Pignon JP, Kratzke R, Soria JC, Shepherd FA, Seymour L, Michiels S, Tsao MS.

Transl Lung Cancer Res. 2018 Jun;7(3):416-427. doi: 10.21037/tlcr.2018.05.01.

25.

Identity and Seasonal Abundance of Beneficial Arthropods Associated with Big Sagebrush (Artemisia tridentata) in Central Washington State, USA.

James DG, Seymour L, Lauby G, Buckley K.

Insects. 2018 Jun 28;9(3). pii: E76. doi: 10.3390/insects9030076.

26.

An unusual case of myeloma.

Tate C, McKinley M, Seymour L.

Pathology. 2018 Aug;50(5):581-584. doi: 10.1016/j.pathol.2018.01.011. Epub 2018 Jun 18. No abstract available.

PMID:
29921449
27.

Expression of human CD46 and trans-complementation by murine adenovirus 1 fails to allow productive infection by a group B oncolytic adenovirus in murine cancer cells.

Lei J, Jacobus EJ, Taverner WK, Fisher KD, Hemmi S, West K, Slater L, Lilley F, Brown A, Champion B, Duffy MR, Seymour LW.

J Immunother Cancer. 2018 Jun 13;6(1):55. doi: 10.1186/s40425-018-0350-x.

28.

Group A Streptococcus M1T1 Intracellular Infection of Primary Tonsil Epithelial Cells Dampens Levels of Secreted IL-8 Through the Action of SpyCEP.

Soderholm AT, Barnett TC, Korn O, Rivera-Hernandez T, Seymour LM, Schulz BL, Nizet V, Wells CA, Sweet MJ, Walker MJ.

Front Cell Infect Microbiol. 2018 May 17;8:160. doi: 10.3389/fcimb.2018.00160. eCollection 2018.

29.

Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy.

Bradbury PA, Morris DG, Nicholas G, Tu D, Tehfe M, Goffin JR, Shepherd FA, Gregg RW, Rothenstein J, Lee C, Kuruvilla S, Keith BD, Torri V, Blais N, Hao D, Korpanty GJ, Goss G, Melosky BL, Mates M, Leighl N, Ayoub JP, Sederias J, Feilotter H, Seymour L, Laurie SA.

Lung Cancer. 2018 Jun;120:142-148. doi: 10.1016/j.lungcan.2018.03.005. Epub 2018 Mar 9.

PMID:
29748010
30.

A Randomized Phase II Study of FOLFOX6/Bevacizumab With or Without Pelareorep in Patients With Metastatic Colorectal Cancer: IND.210, a Canadian Cancer Trials Group Trial.

Jonker DJ, Tang PA, Kennecke H, Welch SA, Cripps MC, Asmis T, Chalchal H, Tomiak A, Lim H, Ko YJ, Chen EX, Alcindor T, Goffin JR, Korpanty GJ, Feilotter H, Tsao MS, Theis A, Tu D, Seymour L.

Clin Colorectal Cancer. 2018 Sep;17(3):231-239.e7. doi: 10.1016/j.clcc.2018.03.001. Epub 2018 Mar 8.

PMID:
29653857
31.

A randomized phase II study of pelareorep and docetaxel or docetaxel alone in men with metastatic castration resistant prostate cancer: CCTG study IND 209.

Eigl BJ, Chi K, Tu D, Hotte SJ, Winquist E, Booth CM, Canil C, Potvin K, Gregg R, North S, Zulfiqar M, Ellard S, Ruether JD, Le L, Kakumanu AS, Salim M, Allan AL, Feilotter H, Theis A, Seymour L.

Oncotarget. 2018 Jan 17;9(8):8155-8164. doi: 10.18632/oncotarget.24263. eCollection 2018 Jan 30.

32.

Phenotyping acute and chronic atopic dermatitis-like lesions in Stat6VT mice identifies a role for IL-33 in disease pathogenesis.

DaSilva-Arnold SC, Thyagarajan A, Seymour LJ, Yi Q, Bradish JR, Al-Hassani M, Zhou H, Perdue NJ, Nemeth V, Krbanjevic A, Serezani APM, Olson MR, Spandau DF, Travers JB, Kaplan MH, Turner MJ.

Arch Dermatol Res. 2018 Apr;310(3):197-207. doi: 10.1007/s00403-018-1807-y. Epub 2018 Jan 24.

33.

Clinical and molecular categorization of progressive, adult-onset cutaneous mastocytosis.

Tate C, Tang F, Lane SW, Seymour L.

JAAD Case Rep. 2017 Dec 18;4(1):30-32. doi: 10.1016/j.jdcr.2017.09.038. eCollection 2018 Jan. No abstract available.

34.

A phase I study of foretinib plus erlotinib in patients with previously treated advanced non-small cell lung cancer: Canadian cancer trials group IND.196.

Leighl NB, Tsao MS, Liu G, Tu D, Ho C, Shepherd FA, Murray N, Goffin JR, Nicholas G, Sakashita S, Chen Z, Kim L, Powers J, Seymour L, Goss G, Bradbury PA.

Oncotarget. 2017 Jun 28;8(41):69651-69662. doi: 10.18632/oncotarget.18753. eCollection 2017 Sep 19.

35.

A randomized phase II study of weekly paclitaxel with or without pelareorep in patients with metastatic breast cancer: final analysis of Canadian Cancer Trials Group IND.213.

Bernstein V, Ellard SL, Dent SF, Tu D, Mates M, Dhesy-Thind SK, Panasci L, Gelmon KA, Salim M, Song X, Clemons M, Ksienski D, Verma S, Simmons C, Lui H, Chi K, Feilotter H, Hagerman LJ, Seymour L.

Breast Cancer Res Treat. 2018 Jan;167(2):485-493. doi: 10.1007/s10549-017-4538-4. Epub 2017 Oct 13.

PMID:
29027598
36.

Phase 1 study of intravenous administration of the chimeric adenovirus enadenotucirev in patients undergoing primary tumor resection.

Garcia-Carbonero R, Salazar R, Duran I, Osman-Garcia I, Paz-Ares L, Bozada JM, Boni V, Blanc C, Seymour L, Beadle J, Alvis S, Champion B, Calvo E, Fisher K.

J Immunother Cancer. 2017 Sep 19;5(1):71. doi: 10.1186/s40425-017-0277-7.

37.

Solid Tumor Immunotherapy with T Cell Engager-Armed Oncolytic Viruses.

Scott EM, Duffy MR, Freedman JD, Fisher KD, Seymour LW.

Macromol Biosci. 2018 Jan;18(1). doi: 10.1002/mabi.201700187. Epub 2017 Sep 13. Review.

PMID:
28902983
38.

Making Oncolytic Virotherapy a Clinical Reality: The European Contribution.

Duffy MR, Fisher KD, Seymour LW.

Hum Gene Ther. 2017 Nov;28(11):1033-1046. doi: 10.1089/hum.2017.112. Epub 2017 Aug 1. Review.

PMID:
28793793
39.

Combining Oncolytic Adenovirus with Radiation-A Paradigm for the Future of Radiosensitization.

O'Cathail SM, Pokrovska TD, Maughan TS, Fisher KD, Seymour LW, Hawkins MA.

Front Oncol. 2017 Jul 24;7:153. doi: 10.3389/fonc.2017.00153. eCollection 2017. Review.

40.

Oncolytic adenovirus expressing bispecific antibody targets T-cell cytotoxicity in cancer biopsies.

Freedman JD, Hagel J, Scott EM, Psallidas I, Gupta A, Spiers L, Miller P, Kanellakis N, Ashfield R, Fisher KD, Duffy MR, Seymour LW.

EMBO Mol Med. 2017 Aug;9(8):1067-1087. doi: 10.15252/emmm.201707567.

41.

Anti-Inflammatory Activity and Structure-Activity Relationships of Brominated Indoles from a Marine Mollusc.

Ahmad TB, Rudd D, Smith J, Kotiw M, Mouatt P, Seymour LM, Liu L, Benkendorff K.

Mar Drugs. 2017 May 6;15(5). pii: E133. doi: 10.3390/md15050133.

42.

Preclinical Safety Studies of Enadenotucirev, a Chimeric Group B Human-Specific Oncolytic Adenovirus.

Illingworth S, Di Y, Bauzon M, Lei J, Duffy MR, Alvis S, Champion B, Lieber A, Hermiston T, Seymour LW, Beadle J, Fisher K.

Mol Ther Oncolytics. 2017 Mar 29;5:62-74. doi: 10.1016/j.omto.2017.03.003. eCollection 2017 Jun 16.

43.

Pooled Analysis of the Prognostic and Predictive Effects of TP53 Comutation Status Combined With KRAS or EGFR Mutation in Early-Stage Resected Non-Small-Cell Lung Cancer in Four Trials of Adjuvant Chemotherapy.

Shepherd FA, Lacas B, Le Teuff G, Hainaut P, Jänne PA, Pignon JP, Le Chevalier T, Seymour L, Douillard JY, Graziano S, Brambilla E, Pirker R, Filipits M, Kratzke R, Soria JC, Tsao MS; LACE-Bio Collaborative Group.

J Clin Oncol. 2017 Jun 20;35(18):2018-2027. doi: 10.1200/JCO.2016.71.2893. Epub 2017 Apr 28.

44.

OvAd1, a Novel, Potent, and Selective Chimeric Oncolytic Virus Developed for Ovarian Cancer by 3D-Directed Evolution.

Kuhn I, Bauzon M, Green N, Seymour L, Fisher K, Hermiston T.

Mol Ther Oncolytics. 2016 Dec 14;4:55-66. doi: 10.1016/j.omto.2016.12.001. eCollection 2017 Mar 17.

45.

Oncolytic Group B Adenovirus Enadenotucirev Mediates Non-apoptotic Cell Death with Membrane Disruption and Release of Inflammatory Mediators.

Dyer A, Di Y, Calderon H, Illingworth S, Kueberuwa G, Tedcastle A, Jakeman P, Chia SL, Brown A, Silva MA, Barlow D, Beadle J, Hermiston T, Ferguson DJ, Champion B, Fisher KD, Seymour LW.

Mol Ther Oncolytics. 2016 Dec 10;4:18-30. doi: 10.1016/j.omto.2016.11.003. eCollection 2017 Mar 17.

46.

iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics.

Seymour L, Bogaerts J, Perrone A, Ford R, Schwartz LH, Mandrekar S, Lin NU, Litière S, Dancey J, Chen A, Hodi FS, Therasse P, Hoekstra OS, Shankar LK, Wolchok JD, Ballinger M, Caramella C, de Vries EGE; RECIST working group.

Lancet Oncol. 2017 Mar;18(3):e143-e152. doi: 10.1016/S1470-2045(17)30074-8. Epub 2017 Mar 2. Review. Erratum in: Lancet Oncol. 2019 May;20(5):e242.

47.

Group B adenovirus enadenotucirev infects polarised colorectal cancer cells efficiently from the basolateral surface expected to be encountered during intravenous delivery to treat disseminated cancer.

Chia SL, Lei J, Ferguson DJP, Dyer A, Fisher KD, Seymour LW.

Virology. 2017 May;505:162-171. doi: 10.1016/j.virol.2017.02.011. Epub 2017 Mar 3.

48.

PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer.

Tsao MS, Le Teuff G, Shepherd FA, Landais C, Hainaut P, Filipits M, Pirker R, Le Chevalier T, Graziano S, Kratze R, Soria JC, Pignon JP, Seymour L, Brambilla E.

Ann Oncol. 2017 Apr 1;28(4):882-889. doi: 10.1093/annonc/mdx003.

49.

RECIST - learning from the past to build the future.

Litière S, Collette S, de Vries EG, Seymour L, Bogaerts J.

Nat Rev Clin Oncol. 2017 Mar;14(3):187-192. doi: 10.1038/nrclinonc.2016.195. Epub 2016 Dec 20. Review.

PMID:
27995946
50.

A Rapid-Response Humoral Vaccine Platform Exploiting Pre-Existing Non-Cognate Populations of Anti-Vaccine or Anti-Viral CD4+ T Helper Cells to Confirm B Cell Activation.

Hills T, Jakeman PG, Carlisle RC, Klenerman P, Seymour LW, Cawood R.

PLoS One. 2016 Nov 18;11(11):e0166383. doi: 10.1371/journal.pone.0166383. eCollection 2016.

Supplemental Content

Loading ...
Support Center